CytomX Therapeutics Announces Phase II Results for Praluzatamab Ravtansine in Breast Cancer

CytomX Therapeutics, Inc. announced that the Phase II study of praluzatamab ravtansine in patients with hormone receptor-positive/HER2-non-amplified breast cancer met its primary efficacy endpoint of confirmed objective response rate of greater than 10 percent by central radiology review.